Comparison of effects of anti-angiogenic agents in the zebrafish efficacy–toxicity model for translational anti-angiogenic drug discovery

References

• Folkman J Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1995 1 1 27 31 7584949
   PubMed Web of Science ®Google Scholar
• Verheul HM Pinedo HM Inhibition of angiogenesis in cancer patients Expert Opin Emerg Drugs 2005 10 2 403 412 15934875
   PubMedGoogle Scholar
• Pasquier E Kavallaris M Andre N Metronomic chemotherapy: new rationale for new directions Nat Rev Clin Oncol 2010 7 8 455 465 20531380
   PubMed Web of Science ®Google Scholar
• Faivre S Delbaldo C Vera K Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 2006 24 1 25 35 16314617
   PubMed Web of Science ®Google Scholar
• Verheul HM Pinedo HM Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition Nat Rev Cancer 2007 7 6 475 485 17522716
   PubMed Web of Science ®Google Scholar
• Elice F Rodeghiero F Falanga A Rickles FR Thrombosis associated with angiogenesis inhibitors Best Pract Res Clin Haematol 2009 22 1 115 128 19285278
   PubMed Web of Science ®Google Scholar
• Rajotte D Arap W Hagedorn M Koivunen E Pasqualini R Ruoslahti E Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display J Clin Invest 1998 102 2 430 437 9664085
   PubMed Web of Science ®Google Scholar
• Staton CA Stribbling SM Tazzyman S Hughes R Brown NJ Lewis CE Current methods for assaying angiogenesis in vitro and in vivo Int J Exp Pathol 2004 85 5 233 248 15379956
   PubMed Web of Science ®Google Scholar
• Serbedzija GN Flynn E Willett CE Zebrafish angiogenesis: a new model for drug screening Angiogenesis 1999 3 4 353 359 14517415
   PubMedGoogle Scholar
• Lyons MS Bell B Stainier D Peters KG Isolation of the zebrafish homologues for the tie-1 and tie-2 endothelium-specific receptor tyrosine kinases Dev Dyn 1998 212 1 133 140 9603430
   PubMed Web of Science ®Google Scholar
• Liang D Chang JR Chin AJ The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development Mech Dev 2001 108 1–2 29 43 11578859
   PubMed Web of Science ®Google Scholar
• Chan J Bayliss PE Wood JM Roberts TM Dissection of angiogenic signaling in zebrafish using a chemical genetic approach Cancer Cell 2002 1 3 257 267 12086862
   PubMed Web of Science ®Google Scholar
• Cross LM Cook MA Lin S Chen JN Rubinstein AL Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay Arterioscler Thromb Vasc Biol 2003 23 5 911 912 12740225
   PubMed Web of Science ®Google Scholar
• Kimmel CB Ballard WW Kimmel SR Ullmann B Schilling TF Stages of embryonic development of the zebrafish Dev Dyn 1995 203 3 253 310 8589427
   PubMed Web of Science ®Google Scholar
• Nicoli S Presta M The zebrafish/tumor xenograft angiogenesis assay Nat Protoc 2007 2 11 2918 2923 18007628
   PubMed Web of Science ®Google Scholar
• Nagel R DarT: The embryo test with the Zebrafish Danio rerio – a general model in ecotoxicology and toxocology ALTEX 2002 19 Supp 1 38 48 12096329
   PubMedGoogle Scholar
• Gridelli C Bareschino MA Schettino C Rossi A Maione P Ciardiello F Erlotinib in non-small cell lung cancer treatment: current status and future development Oncologist 2007 12 7 840 849 17673615
   PubMed Web of Science ®Google Scholar
• Eskens FA de Jonge MJ Bhargava P Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors Clin Cancer Res 2011 17 22 7156 7163 21976547
   PubMed Web of Science ®Google Scholar
• Pal SK Bergerot PG Figlin RA Tivozanib: current status and future directions in the treatment of solid tumors Expert Opin Investig Drugs 2012 21 12 1851 1859
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD Zou HY Grazzini ML Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 2008 14 22 7272 7283 19010843
   PubMed Web of Science ®Google Scholar
• Morabito A Piccirillo MC Falasconi F Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions Oncologist 2009 14 4 378 390 19349511
   PubMed Web of Science ®Google Scholar
• Kumar R Knick VB Rudolph SK Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol Cancer Ther 2007 6 7 2012 2021 17620431
   PubMed Web of Science ®Google Scholar
• Polverino A Coxon A Starnes C AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Res 2006 66 17 8715 8721 16951187
   PubMed Web of Science ®Google Scholar
• Ng SS Gütschow M Weiss M Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues Cancer Res 2003 63 12 3189 3194 12810647
   PubMed Web of Science ®Google Scholar
• Danesi R Del Bianchi S Soldani P Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane Br J Cancer 1993 68 5 932 938 7692920
   PubMed Web of Science ®Google Scholar
• Minischetti M Vacca A Ribatti D TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically Br J Haematol 2000 109 4 829 837 10929037
   PubMed Web of Science ®Google Scholar
• Davis DW Takamori R Raut CP Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668 Clin Cancer Res 2005 11 2 Pt 1 678 689 15701856
   PubMed Web of Science ®Google Scholar
• Kumar K Bhargava P Roy U In vitro refolding of triosephosphate isomerase from L. donovani Appl Biochem Biotechnol 2011 164 7 1207 1214 21365180
   PubMed Web of Science ®Google Scholar
• Wilhelm SM Dumas J Adnane L Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int J Cancer 2011 129 1 245 255 21170960
   PubMed Web of Science ®Google Scholar
• Kerr JS Wexler RS Mousa SA Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors Anticancer Res 1999 19 2A 959 968 10368639
   PubMed Web of Science ®Google Scholar
• Brüsselbach S Nettelbeck DM Sedlacek HH Müller R Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells Int J Cancer 1998 77 1 146 152 9639406
   PubMed Web of Science ®Google Scholar
• Melkonian G Munoz N Chung J Tong C Marr R Talbot P Capillary plexus development in the day five to day six chick chorioallantoic membrane is inhibited by cytochalasin D and suramin J Exp Zool 2002 292 3 241 254 11857458
   PubMedGoogle Scholar
• Bauer KS Dixon SC Figg WD Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent Biochem Pharmacol 1998 55 11 1827 1834 9714301
   PubMed Web of Science ®Google Scholar
• Wilhelm SM Carter C Tang L BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 2004 64 19 7099 7109 15466206
   PubMed Web of Science ®Google Scholar
• Pignochino Y Grignani G Cavalloni G Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways Mol Cancer 2009 8 118 20003259
   PubMed Web of Science ®Google Scholar
• Martinho O Silva-Oliveira R Miranda-Gonçalves V In vitro and in vivo analysis of RTK inhibitor efficacy and identification of its novel targets in glioblastomas Transl Oncol 2013 6 2 187 196 23544171
   PubMed Web of Science ®Google Scholar
• Newcomb EW Ali MA Schnee T Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy Neuro Oncol 2005 7 3 225 235 16053697
   PubMed Web of Science ®Google Scholar
• Hurwitz H Fehrenbacher L Novotny W Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 2004 350 23 2335 2342 15175435
   PubMed Web of Science ®Google Scholar
• Ferrara N Hillan KJ Gerber HP Novotny W Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 2004 3 5 391 400 15136787
   PubMed Web of Science ®Google Scholar
• Geberth M Foerster F Klare P Efficacy and safety of first-line bevacizumab (BEV) combined with paclitaxel (PAC) according to age: subpopulation analysis of a large, multicenter, non-interventional study in patients (Pts) with HER2-negative metastatic breast cancer (MBC) Cancer Res 2009 69 24 Suppl 3 6085
   Web of Science ®Google Scholar
• Tozer GM Kanthou C Baguley BC Disrupting tumour blood vessels Nat Rev Cancer 2005 5 6 423 435 15928673
   PubMed Web of Science ®Google Scholar
• Bilenker JH Flaherty KT Rosen M Phase I trial of combretastatin a-4 phosphate with carboplatin Clin Cancer Res 2005 11 4 1527 1533 15746056
   PubMed Web of Science ®Google Scholar
• Motzer RJ Hutson TE Tomczak P Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 2009 27 22 3584 3590 19487381
   PubMed Web of Science ®Google Scholar
• Escudier B Eisen T Stadler WM Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 2009 27 20 3312 3318 19451442
   PubMed Web of Science ®Google Scholar
• Bhargava P Robinson MO Development of second-generation VEGFR tyrosine kinase inhibitors: current status Curr Oncol Rep 2011 13 2 103 111 21318618
   PubMed Web of Science ®Google Scholar
• Auerbach R Auerbach W Polakowski I Assays for angiogenesis: a review Pharmacol Ther 1991 51 1 1 11 1722898
   PubMed Web of Science ®Google Scholar
• Norrby K Drug testing with angiogenesis models Expert Opin Drug Discov 2008 3 5 533 549 23484925
   PubMed Web of Science ®Google Scholar
• Norrby K In vivo models of angiogenesis J Cell Mol Med 2006 10 3 588 612 16989723
   PubMed Web of Science ®Google Scholar
• Busquet F Nagel R von Landenberg F Mueller SO Huebler N Broschard TH Development of a new screening assay to identify proteratogenic substances using zebrafish danio rerio embryo combined with an exogenous mammalian metabolic activation system (mDarT) Toxicol Sci 2008 104 1 177 188 18375544
   PubMed Web of Science ®Google Scholar
• Mriouah J Boura C Thomassin M Tumor vascular responses to antivascular and antiangiogenic strategies: looking for suitable models Trends Biotechnol 2012 30 12 649 658 23021636
   PubMed Web of Science ®Google Scholar
• Chu TF Rupnick MA Kerkela R Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 2007 370 9604 2011 2019 18083403
   PubMed Web of Science ®Google Scholar
• Senderowicz AM Small molecule modulators of cyclin-dependent kinases for cancer therapy Oncogene 2000 19 56 6600 6606 11426645
   PubMed Web of Science ®Google Scholar
• Eisenberger MA Sinibaldi VJ Reyno LM Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer J Clin Oncol 1995 13 9 2174 2186 7666076
   PubMed Web of Science ®Google Scholar
• Ito T Ando H Suzuki T Identification of a primary target of thalidomide teratogenicity Science 2010 327 5971 1345 1350 20223979
   PubMed Web of Science ®Google Scholar
• Yoshikawa D Ojima H Kokubu A Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma Br J Cancer 2009 100 8 1257 1266 19319137
   PubMed Web of Science ®Google Scholar
• Motzer RJ Nosov D Eisen T Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial J Clin Oncol 2013 31 30 3791 3799 24019545
   PubMed Web of Science ®Google Scholar
• Scagliotti GV Vynnychenko I Park K International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1 J Clin Oncol 2012 30 23 2829 2836 22753922
   PubMed Web of Science ®Google Scholar
• Ingber D Fujita T Kishimoto S Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth Nature 1990 348 6301 555 557 1701033
   PubMed Web of Science ®Google Scholar
• Fong TAT Shawver LK Sun L SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types Cancer Res 1999 59 1 99 106 9892193
   PubMed Web of Science ®Google Scholar
• Kuenen BC Tabernero J Baselga J Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma Clin Cancer Res 2003 9 5 1648 1655 12738717
   PubMed Web of Science ®Google Scholar
• Rustin GJ Shreeves G Nathan PD A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer Br J Cancer 2010 102 9 1355 1360 20389300
   PubMed Web of Science ®Google Scholar
• Nicoli S Ribatti D Cotelli F Presta M Mammalian tumor xenografts induce neovascularization in zebrafish embryos Cancer Res 2007 67 7 2927 2931 17409396
   PubMed Web of Science ®Google Scholar
• Lee SL Rouhi P Dahl Jensen L Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model Proc Natl Acad Sci U S A 2009 106 46 19485 19490 19887629
   PubMed Web of Science ®Google Scholar